Argen X (Germany) Top Insiders
| 1AE Stock | EUR 718.60 19.80 2.83% |
Argen X employs about 1.6 K people. The company is managed by 27 executives with a total tenure of roughly 132 years, averaging almost 4.0 years of service per executive, having 59.22 employees per reported executive. Examination of Argen X's management performance can provide insight into the company performance.
| MSc EMBA CEO CEO CoFounder |
| Tim Hauwermeiren CEO Chief Executive Officer, Co-Founder, Executive Director |
Argen |
Argen X Management Team Effectiveness
The company has return on total asset (ROA) of 0.0483 % which means that it generated a profit of $0.0483 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2472 %, meaning that it generated $0.2472 on every $100 dollars invested by stockholders. Argen X's management efficiency ratios could be used to measure how well Argen X manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Argen X's Non Current Assets Total are most likely to increase significantly in the upcoming years. The Argen X's current Other Assets is estimated to increase to about 155.1 M, while Non Currrent Assets Other are projected to decrease to roughly 1.4 M.The current Common Stock Shares Outstanding is estimated to decrease to about 53 M. The Argen X's current Net Loss is estimated to increase to about (606.7 M)Argen X holds a total of 61.88 Million outstanding shares. 30% of Argen X outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Argen X in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Argen X, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Argen X Workforce Comparison
Argen X is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 200,166. Argen X maintains roughly 1,599 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of 0.42 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.3 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.3. Argen X Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Argen X Price Series Summation is a cross summation of Argen X price series and its benchmark/peer.
Argen X Notable Stakeholders
An Argen X stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Argen X often face trade-offs trying to please all of them. Argen X's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Argen X's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Pr Ir | CoFounder Advisors | Profile | |
| MSc EMBA | CEO CoFounder | Profile | |
| Tim Hauwermeiren | Chief Executive Officer, Co-Founder, Executive Director | Profile | |
| Peter Verhaeghe | Non-Executive Independent Chairman of the Board | Profile | |
| Werner Lanthaler | Non-Executive Independent Vice Chairman of the Board | Profile | |
| Eric Castaldi | Chief Financial Officer | Profile | |
| Keith Woods | Chief Operating Officer | Profile | |
| James Daly | Non-Executive Independent Director | Profile | |
| Anthony Rosenberg | Non-Executive Independent Director | Profile | |
| Karen Massey | Chief Officer | Profile | |
| Beth DelGiacco | VP Relations | Profile | |
| Filip Borgions | VP Operations | Profile | |
| Arjen MSc | Vice Strategy | Profile | |
| Karl Gubitz | Chief Officer | Profile | |
| Joseph deBethizy | Non-Executive Independent Director | Profile | |
| Malini Moorthy | General Counsel | Profile | |
| Peter Ulrichts | Chief Officer | Profile | |
| Hans Haard | Chief Scientific Officer | Profile | |
| Wim Parys | Chief Medical Officer | Profile | |
| Dirk Beeusaert | General Counsel | Profile | |
| EMBA MBA | CEO Director | Profile | |
| Luc Truyen | Chief Officer | Profile | |
| David Lacey | Non-Executive Independent Director | Profile | |
| Arjen Lemmen | Vice President - Corporate Development and Strategy | Profile | |
| Pamela Klein | Non-Executive Independent Director | Profile | |
| David MD | Advisor | Profile | |
| Andria Wilk | Global Quality | Profile |
About Argen X Management Performance
The success or failure of an entity such as Argen X often depends on how effective the management is. Argen X management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Argen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Argen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. The company has strategic partnership with AbbVie S..R.L. and LEO Pharma AS and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. ARGENX SE is traded on Frankfurt Stock Exchange in Germany.
Argen X Workforce Analysis
Traditionally, organizations such as Argen X use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Argen X within its industry.Argen X Manpower Efficiency
Return on Argen X Manpower
| Revenue Per Employee | 1.4M | |
| Revenue Per Executive | 81.1M | |
| Net Income Per Employee | 521K | |
| Net Income Per Executive | 30.9M | |
| Working Capital Per Employee | 2.6M | |
| Working Capital Per Executive | 156M |
Complementary Tools for Argen Stock analysis
When running Argen X's price analysis, check to measure Argen X's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argen X is operating at the current time. Most of Argen X's value examination focuses on studying past and present price action to predict the probability of Argen X's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argen X's price. Additionally, you may evaluate how the addition of Argen X to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |